ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Insider Trading Filed: 2026-04-07

The reporting person, Melissa McLaughlin, Chief Human Resources Officer at Alnylam Pharmaceuticals, has sold a substantial number of Alnylam shares on the open market over the past few days, totaling over 2,500 shares.
The sales were made pursuant to a pre-established 10b5-1 trading plan, suggesting the transactions were part of a planned strategy rather than discretionary selling.
The trading volume and timing of the sales may be of interest to investors as it could signal the reporting person's views on the company's near-term prospects or their personal financial planning.

Insider Trading Filed: 2026-03-06

The reporting person, Kevin Joseph Fitzgerald, sold a total of 1,205 shares of Alnylam Pharmaceuticals, Inc. (ALNY) common stock on March 4 and 5, 2026, likely to cover tax withholding obligations on the vesting of restricted stock units.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating pre-planned transactions rather than discretionary selling.
The reporting person continues to hold a substantial position of 21,227 shares of ALNY common stock following the reported transactions, suggesting ongoing confidence in the company.

Insider Trading Filed: 2026-03-06

Tolga Tanguler, the EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, sold 2,109 shares of the company's common stock on March 4, 2026 at prices ranging from $319.03 to $326.21.
The sales were made pursuant to a mandatory sell-to-cover provision in Tanguler's award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
Following the reported transactions, Tanguler's beneficial ownership of Alnylam's common stock decreased from 36,500 shares to 34,297 shares.

Insider Trading Filed: 2026-03-06

The filing indicates that Jeffrey V. Poulton, the EVP and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), has sold a significant number of shares on March 4, 2026, totaling 2,248 shares at prices ranging from $319.03 to $326.21.
The share sales appear to be part of a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale.
The reporting person still holds a substantial number of shares (61,862) after the reported transactions, suggesting they maintain a significant ownership stake in the company.

Insider Trading Filed: 2026-03-06

Yvonne Greenstreet, the CEO of Alnylam Pharmaceuticals, made a series of stock sales on March 4, 2026 to cover tax withholding obligations on vesting of restricted stock units.
The sales were made in multiple transactions at prices ranging from $318.27 to $326.21, with a total of 2,933 shares sold.
The CEO still holds a significant stake of 95,695 shares in the company, indicating ongoing commitment despite the stock sales.

Insider Trading Filed: 2026-03-06

Insider Garg Pushkal, EVP Chief R&D, has sold a significant amount of Alnylam Pharmaceuticals (ALNY) shares over the past two trading days, totaling 6,207 shares.
The sales appear to be automatic sell-to-cover transactions to cover tax withholding obligations upon the vesting of restricted stock units, rather than open market sales.
The trading activity suggests Garg may have confidence in the near-term performance of Alnylam's stock price, as the sales were made at prices above $318 per share.

Current Report Filed: 2026-02-12

Alnylam Pharmaceuticals reported its Q4 2025 financial results, indicating the company's continued growth and strong performance.
The company did not disclose any material agreements, leadership changes, or other significant events that would be considered a major event.
Based on the information provided, there are no major red flags or concerns that would significantly impact the company's outlook or investor sentiment.

Annual Report Filed: 2026-02-12